SCHEMBL23723545

SCHEMBL23723545

CCCN(CC(=O)Nc1ccc(F)cc1F)Cc1nc2ccsc2c(=O)[nH]1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.46
HTT P42858 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALDH1A1 P00352 8/20 0.46
ALPL P05186 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
KDM4E B2RXH2 1/20 0.41
GAA P10253 3/20 0.41
HPGD P15428 1/20 0.41
LMNA P02545 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23723622 0.73 ALDH1A1 (0.57) RXFP1HTTTDP1ALDH1A1ALPL
SCHEMBL30132070 0.73 ALDH1A1 (0.57) RXFP1HTTTDP1ALDH1A1ALPL
SCHEMBL30368772 0.73 ALDH1A1 (0.57) TDP1ALDH1A1ALPLMAPTMAPK1
SCHEMBL23723536 0.73 TDP1 (0.61) RXFP1HTTTDP1ALDH1A1ALPL
SCHEMBL23723730 0.72 ALDH1A1 (0.56) RXFP1HTTTDP1ALDH1A1ALPL
SCHEMBL23723683 0.72 HTT (0.57) RXFP1HTTTDP1ALDH1A1ALPL
SCHEMBL26523253 0.70 HTT (0.55) RXFP1HTTTDP1ALDH1A1ALPL
SCHEMBL30132103 0.69 ALDH1A1 (0.58) RXFP1HTTTDP1ALDH1A1ALPL
SCHEMBL23723554 0.69 ALDH1A1 (0.58) RXFP1HTTTDP1ALDH1A1ALPL
SCHEMBL23749884 0.68 HTT (0.50) RXFP1HTTTDP1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
EP-4100015-A1 COMBINATION THERAPY FOR TREATING MPS1 Gain Therapeutics SA (CH) 2022-12-14 EP disclosed
WO-2021156774-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2021-08-12 WO disclosed
WO-2021156774-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 IDUA, MAN2B1, GBA1 RXFP1 134/4885HTT 2263/4885TDP1 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.